Is there a generic for Cangrelor?

Yes. The FDA Orange Book lists 2 approved generic (ANDA) applications for Cangrelor, referencing the brand KENGREAL. Generics rated with an "A" therapeutic-equivalence code are considered substitutable for the brand.

What is the reference-listed drug for Cangrelor?

KENGREAL (NDA 204958, CHIESI) is the reference-listed drug — the approved product a generic applicant must show its version is the same as.

What patents protect Cangrelor?

The Orange Book lists 7 patents against Cangrelor products, with the earliest listed expiry in 2029. Listed patents cover the drug substance, drug product, or approved methods of use, and a generic launching before they expire must file a Paragraph IV certification.

What dosage forms of Cangrelor are approved?

Cangrelor is approved in the following dosage form: powder.

FDA Orange Book · active-ingredient family

Cangrelor

Cangrelor: 1 brand, 2 generics; first approved Jun 22, 2015; generic available.

Generic available

Generic status & protection

Generic available — 2 ANDA applications approved.

Earliest patent expiry May 13, 2029

Brands (NDA)

Generics (ANDA)

Listed patents

Next patent expiry

May 13, 2029

in 2 yr 11 mo

Originator applications

Brand (NDA) products

KENGREALRLDRS

CHIESINDA 2049582015

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
50MG/VIAL	POWDER	INTRAVENOUS	Rx	AP

Abbreviated applications

Generic (ANDA) products (2)

CANGRELOR

MSNANDA 2137032026

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
50MG/VIAL	POWDER	INTRAVENOUS	Rx	AP

CANGRELOR

GLANDANDA 2135512025

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
50MG/VIAL	POWDER	INTRAVENOUS	Rx	AP

Protection horizon

Patent & exclusivity timeline

Patent expiryExclusivity endToday

Orange Book patent file

Listed patents

Listed patents (7)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
Patent	Expires	In	Type
9925265	May 13, 2029	in 2 yr 11 mo	U-2260
9427448	Nov 10, 2030	in 4 yr 5 mo	U-1926
8680052	Mar 09, 2033	in 6 yr 9 mo	U-2979
10039780	Jul 10, 2035	in 9 yr 1 mo	U-2260
9439921	Jul 10, 2035	in 9 yr 1 mo	Product
9700575	Jul 10, 2035	in 9 yr 1 mo	Product
9295687	Jul 10, 2035	in 9 yr 1 mo	Product

FDA approval span

Approval history

First approval

Jun 22, 2015

11 yr 3 mo ago

Most recent approval

Jun 04, 2026

1 mo ago

Approvals span 2015–2026 across 3 FDA applications.

Brand (NDA) 133%

Generic (ANDA) 267%

Cangrelor — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Related FDA reference tools

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.

Book a Demo